

adversely affects human health. Additional details of this program are found in **Federal Register** December 16, 1997, (Volume 62, No. 241, pp. 65814-65815).

#### **Working Group Meeting on EMF Health Effects Research Open to the Public**

The next phase of the NIEHS report development process includes a Working Group meeting of scientists from multiple disciplines. The Working Group members are tasked with writing a comprehensive review of the literature on the potential for extremely low frequency EMF to affect human health. This document will draw conclusions on the strength and robustness of the data and its implications for human health effects and disease etiology. This meeting is scheduled for June 15-24, 1998, at the Northland Inn, Brooklyn Park, Minnesota, and is open to the public.

Detailed information about the EMFRAPID Program is found on the world wide web at [www.niehs.nih.gov/emfrapid/home.htm](http://www.niehs.nih.gov/emfrapid/home.htm). For additional information about the Working Group meeting, send a request by fax to 919-541-0144 or by mail to EMFRAPID Program, LCBRA, NIEHS, NIH, PO Box 12233 MS EC-16, Research Triangle Park, NC 27709, or call 919-541-7534.

Dated: April 30, 1998.

**Samuel H. Wilson,**

*National Institute of Environmental Health Sciences.*

[FR Doc. 98-12177 Filed 5-6-98; 8:45 am]

BILLING CODE 4140-01-M

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Warren Grant Magnuson Clinical Center; Notice of Meeting of the Board of Governors of the Warren Grant Magnuson Clinical Center**

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the Board of Governors of the Warren Grant Magnuson Clinical Center, May 27, 1998. The Board of Governors will meet at the National Institutes of Health, Clinical Center (Building 10), Medical Board Room (2C116), 9000 Rockville Pike, Bethesda, Maryland, from 9:00 a.m. until approximately 12:30 p.m.

The entire meeting will be open to the public and will include review of the minutes of the March 23, 1998 Executive Committee meeting, updates on the budget, strategic planning, and the Clinical Research Center.

Attendance by the public will be limited to space available.

For further information, contact Ms. Maggi Stakem, Office of the Director, Warren Grant Magnuson Clinical Center, Building 10, Room 2C146, Bethesda, Maryland 20892, (301) 496-4114.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Stakem in advance of the meeting.

Dated: May 1, 1998.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 98-12102 Filed 5-6-98; 8:45 am]

BILLING CODE 4140-01-M

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

#### **Prospective Grant of Exclusive License: Container for Drying Biological Samples, Method of Making Such Container, and Method of Using Same**

**AGENCY:** National Institutes of Health, Public Health Service, DHHS.

**ACTION:** Notice.

**SUMMARY:** This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the invention embodied in U.S. Patent Applicant SN 08/717,114 entitled "Container for Drying Biological Samples, Method of Making Such Container, and Method of Using Same" and related U.S. and foreign patent applications to Whatman, Incorporated of Clifton, New Jersey. The patent rights in this invention have been assigned to the United States of America.

Is anticipated that this license may be limited to the field of sales to; biotechnology laboratories, and original equipment manufacturers of diagnostics.

**DATES:** Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 6, 1998 will be considered.

**ADDRESSES:** Requests for a copy of this patent application, inquiries, comments and other materials relating to the contemplated license should be directed

to: David R. Sadowski, Technology Transfer Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone (301) 496-7056 extension 288; Facsimile: (301) 401-0220; E-mail [ds27a@nih.gov](mailto:ds27a@nih.gov). A signed Confidential Disclosure Agreement will be required to receive a copy of the patent application.

**SUPPLEMENTARY INFORMATION:** The patent application describes a method (and associated device) for venting a sample which is in a container, the method comprising: providing a container having an opening, the opening being sealed substantially with a filter. The filter permitting permeation therethrough of at least one gas and substantially preventing permeation therethrough of microbes. Wherein said container is configured to withstand high speed centrifugation of 50 or more times the force of gravity. Thus, gas is permitted to enter or exit the container by permeating the filter, thereby affording venting of the sample without substantial contamination of the sample with microbes. More broadly, this invention permits the lyophilization or venting or other permeation of gas into, or out of, a container, while preventing contamination of a sample which is within the container.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Comments and objections submitted in response to this notice will be not made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: April 29, 1998.

**Jack Spiegel,**

*Director, Division of Technology Development and Transfer, Office of Technology Transfer.*

[FR Doc. 98-12108 Filed 5-6-98; 8:45 am]

BILLING CODE 4140-01-M